Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days post-kidney transplantation.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Transplantation

• Publication date

  2002-03-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00007890-200203270-00015PMID 11923692
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• sTNFRI AND sTNFRII SYNTHESIS BY FINE-NEEDLE ASPIRATION BIOPSY SAMPLE CULTURES IS SIGNIFICANTLY ASSOCIATED WITH ACUTE REJECTION IN KIDNEY TRANSPLANTATION1

  2001cited by this paper
• A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS

  2001cited by this paper
• Cell-cycle regulation in immunity, tolerance and autoimmunity.

  2000cited by this paper
• Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.

  2000cited by this paper
• Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine.

  1999cited by this paper
• Kidney graft-infiltrating cells synthesize significantly higher amounts of prostaglandin E2 pre and during acute rejection.

  1999cited by this paper
• Engagement of Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Induces Transforming Growth Factor β (TGF-β) Production by Murine CD4+ T Cells

  1998cited by this paper
• Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.

  1998cited by this paper
• Cytokine analysis of human renal allograft aspiration biopsy cultures supernatants predicts acute rejection.

  1998cited by this paper
• IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12.

  1997cited by this paper
• Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k

  1997cited by this paper
• Analysis of fine-needle aspiration biopsies by flow cytometry in kidney transplant patients.

  1997cited by this paper
• Monocytes-macrophages and cytokines/chemokines in fine-needle aspiration biopsy cultures: enhanced interleukin-1 receptor antagonist synthesis in rejection-free kidney transplant patients.

  1997cited by this paper
• Expression of TGF-beta 1 and matrix proteins is elevated in rats with chronic rejection.

  1996cited by this paper
• Cytokine and alloantibody networks in long term cardiac allografts in rat recipients treated with rapamycin.

  1996cited by this paper
• Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice.

  1996cited by this paper
• The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.

  1995cited by this paper
• The Rapamycin and FKBP12 Target (RAFT) Displays Phosphatidylinositol 4-Kinase Activity (*)

  1995cited by this paper
• Rapamune (Sirolimus, Rapamycin): An Overview and Mechanism of Action

  1995cited by this paper
• Chemokines and renal disease.

  1995cited by this paper
• QUANTITATIVE COMPARISON OF RAPAMYCIN AND CYCLOSPORINE EFFECTS ON CYTOKINE GENE EXPRESSION STUDIED BY REVERSE TRANSCRIPTASE‐COMPETITIVE POLYMERASE CHAIN REACTION1

  1994cited by this paper
• Transforming growth factor beta 1 inhibits interleukin-1-induced but enhances ionomycin-induced interferon-gamma production in a T cell lymphoma: comparison with the effects of rapamycin.

  1994cited by this paper
• Transforming growth factor-beta mediates IL-1-dependent induction of IL-1 receptor antagonist.

  1993cited by this paper
• Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.

  1993cited by this paper
• Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4.

  1993cited by this paper
• Evidence for a repair enzyme complex involving ERCC1 and complementing activities of ERCC4, ERCC11 and xeroderma pigmentosum group F.

  1993cited by this paper
• Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors

  1992cited by this paper
• Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro.

  1991cited by this paper
• The biology of interleukin-6.

  1989cited by this paper
• HIV-1, HTLV-1 and normal T-cell growth: transcriptional strategies and surprises.

  1989cited by this paper
• Inhibition of the immune response by rapamycin, a new antifungal antibiotic.

  1977cited by this paper

• Insights into IL-1 family cytokines in kidney allograft transplantation: IL-18BP and free IL-18 as emerging biomarkers.

  2024cites this paper
• Effects of Antirejection Drugs on Innate Immune Cells After Kidney Transplantation

  2019cites this paper
• Role of donor macrophages after heart and lung transplantation

  2019cites this paper
• Is interleukin‐6 receptor blockade (tocilizumab) beneficial or detrimental to pig‐to‐baboon organ xenotransplantation?

  2019cites this paper
• Musculoskeletal complication in kaposiform hemangioendothelioma without Kasabach–Merritt phenomenon: clinical characteristics and management

  2018cites this paper
• Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients.

  2018cites this paper
• Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations.

  2017cites this paper
• Targeting the Monocyte–Macrophage Lineage in Solid Organ Transplantation

  2017cites this paper
• Does Immunosuppressive Therapy Affect Markers of Kidney Damage?

  2016cites this paper
• Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches

  2016cites this paper
• The influence of exposure to immunosuppressive treatment during pregnancy on renal function and rate of apoptosis in native kidneys of female Wistar rats

  2016cites this paper
• Effect of Immunosuppressive Therapy on Proteinogram in Rats

  2016influential citation
• Sirolimus and proteinuria in kidney transplantation

  2015influential citation
• Rapamycin in fibrotic diseases: beneficial or detrimental agent?

  2013cites this paper
• Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.

  2012cites this paper
• Rapamycin in combination with donor-specific CD4+CD25+Treg cells amplified in vitro might be realize the immune tolerance in clinical organ transplantation.

  2010cites this paper
• Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice

  2008cites this paper
• Key Roles of TGF-β and Smad3 in Prostate Cancer

  2008cites this paper
• Role of the phosphatidylinositol 3-kinase and mTOR pathways in the regulation of renal fibroblast function and differentiation.

  2007cites this paper
• Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells.

  2007cites this paper
• Immunosuppressive Activity of the Immunophilin‐binding Drug Sanglifehrin A in Human Whole Blood: Potent Inhibition of Interleukin‐6 Produced by Lymphocytes and Monocytes

  2006cites this paper
• Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results

  2006cites this paper
• Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis.

  2006cites this paper
• Sirolimus early graft nephrotoxicity: clinical and experimental data.

  2006cites this paper
• Improved Renal Function after Conversion from Tacrolimus/Sirolimus to Tacrolimus/Mycophenolate Mofetil in Kidney Transplant Recipients

  2006cites this paper
• Novel aspects of renal tubulointerstitial fibrosis

  2006cites this paper
• Fine Needle Aspiration Biopsy in Kidney and Pancreas Transplantation

  2006cites this paper
• MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development

  2005cites this paper
• Sirolimus: the evidence for clinical pharmacokinetic monitoring.

  2005cites this paper
• Rapamycin Attenuates Atherosclerotic Plaque Progression in Apolipoprotein E Knockout Mice: Inhibitory Effect on Monocyte Chemotaxis

  2005cites this paper
• Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway.

  2004cites this paper
• Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-&bgr;11

  2004cites this paper
• Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.

  2004cites this paper
• Cyclosporine A sensitizes the kidney to tubulointerstitial fibrosis induced by renal warm ischemia

  2004cites this paper